Jennifer L. Taylor‐Cousar

机构：National Jewish Health, University of Colorado Anschutz, University of Colorado Denver · ORCID：0000-0002-5436-9722

发表论文 241 篇 · 总被引 12574 次 · h-index 45

代表论文

• Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials (2025 · The Lancet Respiratory Medicine · 被引 115)
• Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 56)
• Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment (2025 · Journal of Cystic Fibrosis · 被引 39)
• Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study (2025 · American Journal of Respiratory and Critical Care Medicine · 被引 29)
• Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy (2024 · CHEST Journal · 被引 28)
• PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report (2025 · Journal of Cystic Fibrosis · 被引 21)